India, Oct. 9 -- The Noida-based integrated pharmaceutical company has announced a fresh capital commitment in Canada, aimed at one of its most closely watched products. The move comes as demand for the product keeps climbing and as the business works through supply challenges elsewhere in its network. Government support is also part of the funding picture. Here is what the plan covers, why it matters for the company's long-term radiopharma ambitions, and how the latest quarterly numbers fit neatly into the wider story.

Shares of Jubliant Pharmova Ltd are trading at Rs. 929.50, down 0.29 percent on Friday. The stock touched the intraday high of Rs. 950.00 after opening at Rs. 940.40 before slipping to a low of Rs. 919.50. The company co...